Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
Reporting to the Manager, Office of Compliance and Oversight (OCO), the Audit and Monitoring Group (AMG) Team Leader will lead one of the two teams in AMG, namely the Canadian On-Site Monitoring Team OR the Residual and International Monitoring Teams. The AMG Team Leader will ensure AMG standard operating procedures are followed to ensure compliance with applicable guidelines, regulations and standards.
The #CCTG2021 Virtual Spring Meeting is less than a month away!
The first round of invitations has been sent so check your inbox for your invitation email. If you cannot find your e-invitation in your inbox, please check your trash or spam folders. If you need to have your e-invitation re-sent please e-mail us at meeting.spring@ctg.queensu.ca.
Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.
Evaluate the ability to predict survival benefit from adjuvant chemotherapy in early stage non-small cell lung cancer (NSCLC), and
The MAC9 (S0307) PHASE III TRIAL OF BISPHOSPHONATES AS ADJUVANT THERAPY FOR PRIMARY BREAST CANCER trial has been permanently closed.
PURPOSE: This randomized phase III trial studied zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
CCTG is currently recruiting for a Regulatory Affairs Team Leader and a Cancer Research Monitor/Auditor to join our central offices at Queen's University in Kingston Ontario.